# US 8,278,341 B2 · Analogs of indole-3-carbinol and their use as agents against infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,341 B2
- Document ID: US8278341B2
- Status: Granted
- Kind: B2
- Application number: 12/561,656
- Filed: 2009-09-17
- Published: 2010-03-18
- Granted: 2012-10-02
- Earliest claimed: 2008-09-17
- Assignees: SRI International
- Inventors: Ling Jong; Faming Jiang; Gaoquan Li; Kristien Mortelmans
- Web page: https://patentgrep.com/patent/US8278341B2

## CPC

- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 31/497: containing further heterocyclic rings
- A61K 31/535: having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61P 31/04: Antibacterial agents
- C07D 487/04: Ortho-condensed systems
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Compounds useful as antibacterial agents are provided. The compounds are analogs of indole-3-carbinol and have a backbone selected from dihydroindolo[2,3-b]carbazole, 2,2′-diindolylmethane, 2′,3-diindolylmethane, and 3,3′-diindolylmethane. The compounds are useful therapeutic and prophylactic treatment of bacterial infections in mammals. Methods of synthesis of the compounds are provided, as are pharmaceutical compositions containing the compounds.

## Claims

### Claim 1

A compound having the structure of formula (I)
wherein:
R1, R4, R5, and R8 are hydrogen;
R2, R3, R6, R7, and R9 are substituents independently selected from the group consisting of hydrogen, C1-C24 alkyl, C2-C24 alkenyl, C2-C24 alkynyl, C5-C20 aryl, C6-C24 alkaryl, C6-C24 aralkyl, halo, hydroxyl, sulfhydryl, C1-C24 alkoxy, C2-C24 alkenyloxy, C2-C24 alkynyloxy, C5-C20 aryloxy, acyloxy, C2-C24 alkoxycarbonyl, C6-C20 aryloxycarbonyl, C2-C24 alkylcarbonyl, C6-C20 arylcarbonyl, halocarbonyl, C2-C24 alkylcarbonato, C6-C20 arylcarbonato, carboxy, carboxylato, carbamoyl, mono-(C1-C24 alkyl)-substituted carbamoyl, di-(C1-C24 alkyl)-substituted carbamoyl, mono-substituted arylcarbamoyl, thiocarbamoyl, carbamido, cyano, isocyano, cyanato, isocyanato, dihydroxyboryl, di-(C1-C24)-alkoxyboryl, isothiocyanato, azido, formyl, thioformyl, amino, mono- and di-(C1-C24 alkyl)-substituted amino, mono- and di-(C5-C20 aryl)-substituted amino, C2-C24 alkylamido, C6-C20 arylamido, imino, alkylimino, arylimino, nitro, nitroso, sulfo, sulfonato, C1-C24 alkylsulfanyl, arylsulfanyl, C1-C24 alkylsulfinyl, C5-C20 arylsulfinyl, C1-C24 alkylsulfonyl, C5-C20 arylsulfonyl, phosphono, phosphonato, phosphinato, phospho, phosphino, and combinations thereof;
R11 and R12 are independently selected from the group consisting of hydrogen, formyl, C1-C24 alkyl, C6-C24 aralkyl, C2-C24 alkoxycarbonyl, amino-substituted C1-C24 alkyl, (C1-C24 alkylamino)-substituted C1-C24 alkyl, di-(C1-C24 alkyl)amino-substituted C1-C24 alkyl, and nitrogen protecting groups; and
R10 is —O-L-N(Ry1)(Ry2)(Ry3)n2, —O-L-SRz1, or has the structure
wherein:
L is a linker selected from a C1-C12 straight chain, C2-C12 branched, or C3-C12 cyclic alkylene group that may be substituted, unsubstituted, heteroatom containing, or a combination thereof, and an alkylene oxide oligomer;
L1 is a linker selected from a bond, a C1-C12 straight chain, C2-C12 branched, or C3-C12 cyclic alkylene group that may be substituted, unsubstituted, heteroatom containing, or a combination thereof, and an alkylene oxide oligomer;
Ry1 and Ry2 are independently selected from hydrogen, C1-C24 alkyl, C2-C24 alkenyl, C5-C20 aryl, C6-C24 alkaryl, C6-C24 aralkyl, amino, imino, C1-C24 alkylsulfonyl, and C5-C20 arylsulfonyl, any of which may be further substituted and/or heteroatom-containing where such groups permit, or wherein Ry1 and Ry2 are taken together to form a cyclic or polycyclic group that may be unsubstituted, substituted, and/or further heteroatom-containing;
Ry3 is selected from hydrogen and C1-C12 alkyl;
n2 is selected from 0 and 1;
Rz1 is selected from C1-C24 alkyl, C2-C24 alkenyl, C5-C20aryl, C6-C24 alkaryl, and C6-C24 aralkyl, any of which may be further substituted and/or heteroatom-containing where such groups permit;
Q1 and Q2 are selected from a bond and —CH2—;
Q3 is selected from a bond, —CH(Ra3)—, —O—, and —NRa4—, provided that Q3 is not a bond when both Q1 and Q2 are bonds;
Ra1 and Ra2 are independently selected from hydrogen, hydroxyl, amino, C1-C12 alkyl-substituted amino, and C1-C12 alkyl;
Ra3 and Ra4 are independently selected from hydrogen, C1-C12 alkyl, unsubstituted amino, and mono- or di-(C1-C12 alkyl)-substituted amino;
Q4, Q5, and Q6 are selected from —CHRb1— and —NRb1—, where Rb1 is selected from hydrogen, hydroxyl, amino, C1-C12 alkyl-substituted amino, and C1-C12 alkyl;
p1 is an integer in the range of 0-2;
Q7 is selected from —CH< and —N<;
Q8, Q9, Q10, and Q11 are independently selected from —CH(Re1)—, ═C(Re1)—, —NRe1—, and —N═, where Re1 is selected from hydrogen, hydroxyl, amino, C1-C12 alkyl-substituted amino, and C1-C12 alkyl, provided that: (1) any two of Q8, Q9, Q10, and Q11 that are adjacent each other may be linked by a double bond, with the proviso that no more than two double bonds are present, and, when two double bonds are present, a single bond is present between them; and (2) any two adjacent Re1 groups may be taken together to form a 5- or 6-membered ring that may be further substituted and may have one or more heteroatoms; and
Rc1, Rc2, and Rc3 are independently selected from hydrogen, C1-C24 alkyl, and C5-C20 aryl, any of which may be further substituted and/or heteroatom-containing, or wherein any two of Rc1, Rc2, and Rc3 may be taken together to form a cyclic or polycyclic group that may be unsubstituted, substituted, and/or further heteroatom-containing, or
a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein:
n2 is 1;
Ry1, Ry2, and Ry3 are independently selected from hydrogen and C1-C12 alkyl; and
Rz1 is selected from C1-C24 alkyl, C2-C24 alkenyl, C5-C20 aryl, C6-C24 alkaryl, and C6-C24 aralkyl.

### Claim 3 (depends on 1)

The compound of claim 1, wherein:
n2 is 1;
Ry1, Ry2, and Ry3 are independently selected from hydrogen and C1-C12 alkyl;
Rz1 is selected from C1-C24 alkyl, C2-C24 alkenyl, C5-C20 aryl, C6-C24 alkaryl, and C6-C24 aralkyl; and
R10 is —O-L-N(Ry1)(Ry2)(Ry3), or —O-L-SRz1.

### Claim 4 (depends on 1)

The compound of claim 1, wherein:
n2 is 1;
Ry1, Ry2, and Ry3 are independently selected from hydrogen and C1-C12 alkyl;
Rz1 is selected from C1-C24 alkyl, C2-C24 alkenyl, C5-C20 aryl, C6-C24 alkaryl, and C6-C24 aralkyl; and
R10 has the structure

### Claim 5 (depends on 1)

The compound of claim 1, wherein L is —(CH2)m—, where m is an integer from 1 to 6.

### Claim 6 (depends on 1)

The compound of claim 1, wherein R2 and R6 are independently selected from hydrogen, halo, formyl, cyano, C1-C24 alkyl, C2-C24 alkenyl, C1-C24, C5-C20 aryloxy, carbamoyl, C2-C24 alkoxycarbonyl, and amino.

### Claim 7 (depends on 1)

The compound of claim 1, R9 is selected from hydrogen, halo, cyano, C1-C24 alkyl, C2-C24 alkenyl, and amino.

### Claim 8 (depends on 7)

The compound of claim 7, wherein:
L is a C1-C12 straight chain alkylene group or an alkylene oxide oligomer; and
L1 is selected from a bond, a C1-C12 straight chain alkylene group, and an alkylene oxide oligomer.

### Claim 9 (depends on 7)

The compound of claim 7, wherein:
Q1 and Q2 are —CH2—; and
Q3 is selected from —CH(Ra3)—, —O—, and —NRa4—.

### Claim 10 (depends on 7)

The compound of claim 7, wherein Q4 and Q5, are selected —CHRb1—.

### Claim 11 (depends on 7)

The compound of claim 7, wherein: Q8, Q9, Q10, and Q11 are independently selected from ═C(Re1)— and —N═.

### Claim 12 (depends on 1)

The compound of claim 1, wherein R3 and R7 are hydrogen.

### Claim 13 (depends on 1)

The compound of claim 1, wherein R3, R7, R11 and R12 are hydrogen.

### Claim 14 (depends on 1)

The compound of claim 1, wherein R3, R7, R9, R11 and R12 are hydrogen.

### Claim 15 (depends on 1)

The compound of claim 1 wherein R10 is an alkoxy group substituted with a nitrogen containing heterocyclic ring.

### Claim 16 (depends on 12)

The compound of claim 12 wherein R10 is an alkoxy group substituted with a nitrogen containing heterocyclic ring.

### Claim 17 (depends on 13)

The compound of claim 13 wherein R10 is an alkoxy group substituted with a nitrogen containing heterocyclic ring.

### Claim 18 (depends on 14)

The compound of claim 14 wherein R10 is an alkoxy group substituted with a nitrogen containing heterocyclic ring.

### Claim 19 (depends on 1)

The compound of claim 1, wherein R2 and R6 are halo and R10 is an alkoxy group substituted with a nitrogen containing heterocyclic ring.

### Claim 20 (depends on 12)

The compound of claim 12, wherein R2 and R6 are halo and R10 is an alkoxy group substituted with a nitrogen containing heterocyclic ring.

### Claim 21 (depends on 13)

The compound of claim 13, wherein R2 and R6 are halo and R10 is an alkoxy group substituted with a nitrogen containing heterocyclic ring.

### Claim 22 (depends on 14)

The compound of claim 14, wherein R2 and R6 are halo and R10 is an alkoxy group substituted with a nitrogen containing heterocyclic ring.

### Claim 23 (depends on 1)

A formulation comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 24 (depends on 1)

A method for treating a bacterial infection in a mammalian individual in need thereof, comprising administering to the individual a therapeutically effective amount of a compound of claim 1.

### Claim 25 (depends on 24)

The method of claim 24, wherein the bacteria are of the genus Escherichia, Enterobacter, Salmonella, Staphylococcus, Shigella, Listeria, Aerobacter, Helicobacter, Klebsiella, Proteus, Pseudomonas, Streptococcus, Chlamydia, Mycoplasma, Pneumococcus, Neisseria, Clostridium, Bacillus, Corynebacterium, Mycobacterium, Campylobacter, Vibrio, Serratia, Providencia, Chromobacterium, Brucella, Yersinia, Haemophilus, Bordetella, or Francisella.
